

# Dimitrios Mavroudis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5441231/publications.pdf>

Version: 2024-02-01

66  
papers

2,169  
citations

471371

17  
h-index

233338

45  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3146  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index. <i>Children</i> , 2022, 9, 4.	0.6	5
2	TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. <i>Cancers</i> , 2022, 14, 1053.	1.7	7
3	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
4	Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer. <i>Cancers</i> , 2022, 14, 1314.	1.7	3
5	Microbial translocation, toll-like and vitamin D receptor polymorphisms in blood and risk of recurrence in stage III colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3531-3531.	0.8	0
6	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
7	The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Children With Dyslipidemia. <i>Angiology</i> , 2021, 72, 322-331.	0.8	7
8	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. <i>Biomedicines</i> , 2021, 9, 421.	1.4	2
9	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	1.6	19
10	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 668534.	1.6	14
11	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021, 16, e0252537.	1.1	20
12	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. <i>Cancers</i> , 2021, 13, 3522.	1.7	4
13	Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment. <i>Cancers</i> , 2021, 13, 3552.	1.7	3
14	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 1988.	1.8	9
15	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	1.3	21
16	Intrameningioma metastasis: A case-based literature review. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 168-173.	0.8	4
17	Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 925.	1.8	11
18	Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 661-670.	0.5	11

#	ARTICLE	IF	CITATIONS
19	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 8257-8271.	0.9	3
20	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	0.9	1
21	Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 235.	1.1	6
22	Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 2514.	1.8	18
23	International real-world study of DLL3 expression in patients with small cell lung cancer. <i>Lung Cancer</i> , 2020, 147, 237-243.	0.9	17
24	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2058.	1.7	14
25	Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. <i>Cancers</i> , 2020, 12, 3735.	1.7	11
26	The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk. <i>Cancers</i> , 2020, 12, 1379.	1.7	17
27	Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. <i>Cancers</i> , 2020, 12, 1556.	1.7	27
28	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 901-913.	0.5	1
29	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. <i>Cancers</i> , 2020, 12, 376.	1.7	52
30	The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 1058.	1.7	19
31	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020, 12, 1013.	1.7	17
32	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <i>Cancers</i> , 2020, 12, 889.	1.7	20
33	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020, 12, 1282.	1.7	17
34	Detection of microbial DNA in the blood of colorectal cancer patients for the diagnosis of microbial translocation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 171-171.	0.8	0
35	A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 52-56.	0.9	5
36	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 437-447.	1.9	133
38	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9099-9099.	0.8	2
39	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 966-981.	0.8	38
40	Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3500-3500.	0.8	1
41	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 72.	2.2	69
42	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of <i>indolent</i> stage IV disease (Stage IV <sub>indolent</sub> ).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	0.8	3
43	Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. <i>Growth Hormone and IGF Research</i> , 2017, 33, 28-34.	0.5	10
44	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.1	38
45	Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. <i>Translational Oncology</i> , 2017, 10, 693-698.	1.7	7
46	Prognostic value of circulating tumor cells in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20520-e20520.	0.8	0
47	Circulating microRNAs (miRNAs) as predictors of relapse in early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e23030-e23030.	0.8	0
48	Targeting angiogenesis in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 389-400.	1.3	37
49	Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). <i>Clinical Genitourinary Cancer</i> , 2016, 14, e153-e159.	0.9	8
50	Association of Ki-67 expression in CTCs with disease relapse in patients with early breast cancer (BC) and affect by the administration of adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23243-e23243.	0.8	0
51	Next generation sequencing to identify actionable mutations in EGFR-wild type and KRAS mutant non-small cell lung cancer patients ed by the administration of adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20630-e20630.	0.8	0
52	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 113.	2.2	24
53	Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7573-7573.	0.8	1
54	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0123683.	1.1	49

#	ARTICLE	IF	CITATIONS
55	PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16564-e16564.	0.8	0
56	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer, 2014, 14, 651.	1.1	97
57	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	5.1	703
58	Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 11042-11042.	0.8	0
59	Patterns of practice in the management of advanced urothelial cancer (UC) in Greece: A retrospective analysis by the hellenic GU Cancer Group (HGUCG).. Journal of Clinical Oncology, 2014, 32, e15514-e15514.	0.8	0
60	A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, e22105-e22105.	0.8	0
61	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-ii, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.. Journal of Clinical Oncology, 2013, 31, 7594-7594.	0.8	0
62	Peripheral immunosuppressive cell levels as predictive marker for the clinical outcome in stage IV colorectal carcinoma.. Journal of Clinical Oncology, 2013, 31, e14639-e14639.	0.8	0
63	A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, 1045-1045.	0.8	0
64	A multicenter, randomized phase II study of sequential vinorelbine (V)/cisplatin (C)/bevacizumab (B) followed by docetaxel (D)/gemcitabine (G)/B versus D/C/B as a first-line therapy for advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e18105-e18105.	0.8	0
65	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 2011, 13, R59.	2.2	327
66	Arterial Stents for Access and Protection of the Parotid and Submandibular Ducts During Sialoendoscopy. Journal of Oral and Maxillofacial Surgery, 2007, 65, 1865-1868.	0.5	10